Agoracom Blog Home

Posts Tagged ‘PHARMACIELO’

#Cannabis #Pharmaceuticals Market: Rise in investments by #pharma companies in #CBD to drive the market – SPONSOR: Avicanna $AVCN.ca $AVCNF $CARA $GWPH $TBP.ca $CRBP $PCLO.ca

Posted by AGORACOM-JC at 5:04 PM on Wednesday, November 11th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Cannabis-based products or the medical marijuana has orchestrated new avenues in the pharmaceuticals industry
  • Pharma companies, small and big, have plowed investments in cannabidiol (CBD), particularly
  • The inroad made by CBD and CBD-based products is unarguably daunting, riding on the wave of staggered legalization of marijuana
  • The game-changing potential that cannabis has made pharma companies nurse new aspirations by setting their sights in the cannabis pharmaceuticals market

Unsurprisingly, some pharma companies for instance, Insys Therapeutics, put robust opposition to legalization of marijuana. The regulatory status on the CBD is markedly unclear and lack worldwide consensus, for instance, differs from state to state in the U.S., and from nation to nation. Nonetheless, over the years there is a clear surge in interest of pharma companies in medical marijuana, given the medical conditions where cannabis hold incredible potential.

FDA-approved CBD-based drugs will stridently see an increase, expanding the horizon in the CBD market. One of the most recalcitrant diseases CBD-based products in cannabis pharmaceuticals market hold potential, as body of preclinical studies have reiterated, is Dravet syndrome and Lennox-Gastaut syndrome (LGS).

A new study on the cannabis pharmaceuticals market scrutinizes the investment potential of some of the aforementioned trends and the ways in which those will shape the growth dynamics during 2020 – 2030.

Cannabis Pharmaceuticals Market: Key Trends

The shape of the cannabis pharmaceuticals market is expected to be molded by the changing dynamic of the regulatory landscape. A large part of negative public perception of cannabis products has been associated with the recreational use of TSH, a key psychoactive element of cannabis. However, as things have begun to change, the global medicinal industry will intensify its efforts in harnessing therapeutic benefits of cannabis.

The cannabis pharmaceutical industry will see new vistas opening up from expanding array of studies that will provide scientific backing of CBD. This is particularly in relation to the safety and uncontested claims of safety. Further, as regulators will treat different categories of cannabis-based product differently and suitably, the risk benefit profile of cannabis pharmaceuticals will become clearer. The scientific rigor for evidence-based medicine will expand the potential of the market and pave way for research in purified cannabidiol.

Two areas where the industry nurses tall hopes in the cannabis pharmaceuticals market are in reducing opioid epidemic, and in managing some of the hard-to-treat conditions such as some cancers. Stakeholders also appreciate the potential of medical cannabis for aesthetic and medical dermatology.

Cannabis Pharmaceuticals Market: Competitive Analysis and Key Developments

The cannabis pharmaceuticals market has seen numerous big shot companies testing new waters in medical marijuana, and making strategic moves to this end. Research units of a few top pharma companies have made moves toward commercializing cannabinoids for medical use. A recent example is research being made by Avicanna for Johnson & Johnson, and by Vapium for Grenco Science.

Another company, notably a spin-off of Abbott Laboratories, AbbVie Inc. has upped its cannabis-related patents. These developments will undoubtedly strengthen the pipeline of cannabis-related drugs, unlocking new prospects in the cannabis pharmaceuticals market. In the course of time, more start-up companies will ramp up their efforts in patenting Cannabis-based tablets and products.

Another behemoth that is making giant stride in the cannabis pharmaceuticals market is Teva Pharmaceuticals. The company recently announced formally that it has entered into distribution deal with cannabis company Canndoc.

Cannabis Pharmaceuticals Market: Regional Assessment

North America has seemed to garner incredible revenue potential among all key geographies in the cannabis pharmaceutical market over the past several years. The groundswell of interest in medical marijuana is circumscribed by favorable regulations in some quarters, notably in parts of the U.S. Intense discussion among industry stakeholders about the taxing and labelling of cannabis-based medicinal products will cement the potential of the regional market. They are keen on increasing the profitability of marijuana-based products. Another promising region is Europe, expanding on the back of rise in investments by pharma companies in CBD.

Read More: https://www.biospace.com/article/cannabis-pharmaceuticals-market-rise-in-investments-by-pharma-companies-in-cbd-to-drive-the-market-/

Shifting Trends #CBD and The “Big Pharma” – SPONSOR: Avicanna $AVCN.ca $AVCNF $GWPH $PCLO.ca $CRBP

Posted by AGORACOM-JC at 3:34 PM on Monday, October 19th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Shifting Trends – CBD and The “Big Pharma”

  • According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively
  • What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones

By: Jamie Moses

With the increasingly immense popularity of CBD and other hemp-based products, the role of naturally extracted medicine in the realm of the global medicinal industry and big pharmaceuticals is growing at a rapid rate. As various studies and researches have proven the beneficial medical impacts of these CBD compounds, their use for the purposes of health and wellbeing is becoming more and more popular. 

The battle between naturally extracted medicine and pharmaceuticals has always been a controversial debate. The role of big pharma” in health and the theories revolving around their shady impacts has always been contentious. Especially after the wide range popularity and cultivation of CBD and its products such as CBD oils, this issue has been highlighted even more. While the big pharma relies on chemicals and synthetics processes for their medicine to interact and work on the human body, natural medicine is more palatable and relies on its structure and nature to be able to bind with the targetted receptors of the body to provide satisfactory results. 

According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively. What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones. But why is this change of dynamics occurring so suddenly after the discovery of CBD, when the use of herbal medicine is not at all a new trend and dates back many years? According to WHO, more than half of the world population already uses herbal means for their medical anomalies then why is the impact created by CBD so immense? The answer lies in its qualities and various medical benefits it imparts on the body with little or no side effects. The reasons why people are turning towards CBD oils and plant medicine are provided here.

High costs – Both financial and physical:

Pharmaceutical options may be more effective in terms of their selective activism and rapid action by IV fluids, but they come with a high price. Medical insurances and various critical condition drugs are almost too expensive for every citizen to get. This has created a trend among people to shift towards natural means of medicine and wellbeing and that is where CBD oil has been so much dominant. The lower production overheads and a non-monopolized market have kept the prices of these drugs quite lower as compared to the pharmaceuticals. 

Effectiveness:

According to a study, 52% of the people using CBD products daily or regular;y have reported these drugs to be more effective than the pharmaceuticals. The extended researches done have shown that the first-hand reactions of those people are in fact accurate and CBD really works better for them. It has to do with the fact that CBD oil can activate the ECS system of the body and can antagonize the CB1 and Cb2 receptors binding with them effects to provide good results. Moreover, the non-psychoactive nature of CBD means it does not get you “high: or mind-altered like other cannabis-derivatives THC.

Multi-purpose:

Various studies have shown that CBD is a medical marvel that can be used to treat various medical conditions. People are now using CBD Oil for pain, anxiety, depression, stress, insomnia, neurogenesis, anti-cancer treatments, skin condition, and even heart problems. With the recent researches proving the effectiveness of CBD in these medical anomalies and a wide range of consumption options available to the people, it is no shock that CBD products are upholding the drug market right now.

Side-effects:

According to a study conducted over a span of 30 years gathering information from various hospitals, almost 7% of the people using big pharma drugs are likely to have serious reactions to the medicines and require immediate medical attention. Many more have mild to low side effects after using these pharmaceuticals. This has also caused the people to start using alternatives and look for safer and natural options. 

Final thoughts:

Although the medical effectiveness and easy access is a major factor in the favor of cannabis products, the lingering confusion regarding its legal status and dosage regulations still cause hurdles in the way. With the recent law changes, the hemp cultivation has seen an uprise and only by educating people more can this industry of herbal medicine become more effective and provide for the betterment of mankind. 

Source: https://artvoice.com/2020/08/17/shifting-trends-cbd-and-the-big-pharma/